ZOMIG TABLET
国: カナダ
言語: 英語
ソース: Health Canada
製品の特徴
(SPC)
11-01-2023
この製品の一部のドキュメントは現在利用できません。カスタマーサービスにリクエストを送信できます。入手可能になり次第、お知らせします。
リクエストを送信します。
リクエストを送信します。
有効成分:
ZOLMITRIPTAN
から入手可能:
XEDITON PHARMACEUTICALS INC
ATCコード:
N02CC03
INN（国際名）:
ZOLMITRIPTAN
投薬量:
2.5MG
医薬品形態:
TABLET
構図:
ZOLMITRIPTAN 2.5MG
投与経路:
ORAL
パッケージ内のユニット:
3/6
処方タイプ:
Prescription
治療領域:
SELECTIVE SEROTONIN AGONISTS
製品概要:
Active ingredient group (AIG) number: 0134381001; AHFS:
認証ステータス:
APPROVED
承認日:
2023-01-11
製品の特徴
Page 1 of 47
PRODUCT MONOGRAPH
ZOMIG
®
zolmitriptan tablets
2.5 mg
ZOMIG RAPIMELT
®
zolmitriptan orally disintegrating tablets
2.5 mg
ZOMIG
® NASAL SPRAY
zolmitriptan nasal spray
2.5 and 5 mg
5-HT
1
Receptor Agonist
MIGRAINE THERAPY
Xediton Pharmaceuticals Inc.
2020 Winston Park Drive, Suite 402
Oakville, Ontario
L6H 6X7
www.xediton.com
Submission Control No.: 270277
ZOMIG
®
and ZOMIG RAPIMELT
®
are registered trademarks of Grünenthal GmbH, used under
license by Xediton Pharmaceuticals Inc.
Pr
Pr
Pr
Date of
Preparation:
JAN
9,
2023
Page 2 of 47
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
....................................................... 3
SUMMARY PRODUCT INFORMATION
......................................................................
3
INDICATIONS AND CLINICAL USE
...........................................................................
3
CONTRAINDICATIONS
.................................................................................................
4
WARNINGS AND PRECAUTIONS
...............................................................................
4
ADVERSE REACTIONS
...............................................................................................
11
DRUG INTERACTIONS
...............................................................................................
19
DOSAGE AND ADMINISTRATION
...........................................................................
20
OVERDOSAGE
..............................................................................................................
22
ACTION AND CLINICAL PHARMACOLOGY
.......................................................... 22
STORAGE AND STABILITY
.......................................................................................
25
DOSAGE FORMS, COMPOSITION AND PACKAGING
........................................... 26
PART II: SCIENTIFIC INFORMATION
.............................................................................
27
PHARMACEUTICAL INFORMATION
...........................................
完全なドキュメントを読む
